TERM ID="NYU_TERM_1" STRING="Numerous vaccine approaches" FREQUENCY=1 START=526 END=553 LEMMA="NUMEROUS VACCINE APPROACH" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_2" STRING="Subsequent attempts" FREQUENCY=1 START=376 END=395 LEMMA="SUBSEQUENT ATTEMPT" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_3" STRING="T-cells" FREQUENCY=1 START=1255 END=1262 LEMMA="T-CELL" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_4" STRING="antiangiogenic responses" FREQUENCY=1 START=1438 END=1462 LEMMA="ANTIANGIOGENIC RESPONSE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_5" STRING="anticancer activity" FREQUENCY=1 START=1948 END=1967 LEMMA="ANTICANCER ACTIVITY" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_6" STRING="cancer drug" FREQUENCY=1 START=1704 END=1715 LEMMA="CANCER DRUG" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_7" STRING="chronic inflammatory environment" FREQUENCY=1 START=1572 END=1604 LEMMA="CHRONIC INFLAMMATORY ENVIRONMENT" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_8" STRING="clinical benefit" FREQUENCY=1 START=587 END=603 LEMMA="CLINICAL BENEFIT" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_9" STRING="clinical observations" FREQUENCY=1 START=2030 END=2051 LEMMA="CLINICAL OBSERVATION" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_10" STRING="clinical response" FREQUENCY=1 START=607 END=624 LEMMA="CLINICAL RESPONSE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_11" STRING="cyclophosphamide" FREQUENCY=1 START=2368 END=2384 LEMMA="CYCLOPHOSPHAMIDE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_12" STRING="eponymous" FREQUENCY=1 START=268 END=277 LEMMA="EPONYMOUS" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_13" STRING="exclusive" FREQUENCY=1 START=892 END=901 LEMMA="EXCLUSIVE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_14" STRING="exclusive for immunotherapy" FREQUENCY=1 START=892 END=919 LEMMA="IMMUNOTHERAPY EXCLUSIVE" LEMMA_FREQUENCY=1 HEAD_TERM="exclusive" HEAD_LEMMA="EXCLUSIVE"
TERM ID="NYU_TERM_15" STRING="heterogeneity" FREQUENCY=1 START=712 END=725 LEMMA="HETEROGENEITY" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_16" STRING="immunological attack" FREQUENCY=1 START=1312 END=1332 LEMMA="IMMUNOLOGICAL ATTACK" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_17" STRING="immunostimulatory approaches" FREQUENCY=1 START=1479 END=1507 LEMMA="IMMUNOSTIMULATORY APPROACH" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_18" STRING="immunotherapy" FREQUENCY=2 START=4 END=17 LEMMA="IMMUNOTHERAPY" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_19" STRING="immunotherapy" FREQUENCY=2 START=906 END=919 LEMMA="IMMUNOTHERAPY" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_20" STRING="induction" FREQUENCY=1 START=136 END=145 LEMMA="INDUCTION" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_21" STRING="inflammatory response" FREQUENCY=1 START=324 END=345 LEMMA="INFLAMMATORY RESPONSE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_22" STRING="lenalidomide" FREQUENCY=1 START=2142 END=2154 LEMMA="LENALIDOMIDE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_23" STRING="myeloma" FREQUENCY=1 START=2102 END=2109 LEMMA="MYELOMA" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_24" STRING="preclinical models" FREQUENCY=1 START=1990 END=2008 LEMMA="PRECLINICAL MODEL" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_25" STRING="randomised trial" FREQUENCY=1 START=663 END=679 LEMMA="RANDOMISED TRIAL" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_26" STRING="regulatory T-cells" FREQUENCY=1 START=1891 END=1909 LEMMA="REGULATORY T-CELL" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_27" STRING="residual tumour" FREQUENCY=1 START=207 END=222 LEMMA="RESIDUAL TUMOUR" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_28" STRING="stimulatory properties" FREQUENCY=1 START=1838 END=1860 LEMMA="STIMULATORY PROPERTY" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_29" STRING="tumour angiogenesis" FREQUENCY=1 START=1674 END=1693 LEMMA="TUMOUR ANGIOGENESI" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_30" STRING="vaccine approach" FREQUENCY=1 START=930 END=946 LEMMA="VACCINE APPROACH" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_31" STRING="vaccine approaches" FREQUENCY=1 START=1003 END=1021 LEMMA="VACCINE APPROACH" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_32" STRING="vaccine basis" FREQUENCY=1 START=454 END=467 LEMMA="VACCINE BASIS" LEMMA_FREQUENCY=1
